Moderna — Third Quarter 2026 Earnings Summary

Moderna reported third-quarter 2026 revenue of $1.3 billion, representing a 29% increase year-over-year, driven by higher international COVID vaccine sales and the U.S. approval of its fifth product, mFLUSIVA. The company achieved a GAAP net income of $162 million and diluted earnings per share of $0.38, marking a significant turnaround from the net loss recorded in the same period of 2025. Moderna raised its full-year 2026 revenue growth outlook to 15–25% and improved its operating expense guidance, while announcing positive Phase 3 results for its melanoma therapy, intismeran. Additionally, the company's cash and investment balance is projected to reach $8.1–$8.3 billion by year-end following a $2.6 billion convertible notes financing.